| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 1.4K | 12.1% | 9.1% |
| Total Income | 1.4K | 12.1% | 9.1% |
| Expenditure | 1.3K | 8.3% | 1.7% |
| PBT | -11.00 | 82.8% | 92.5% |
| Net Profit | -14.00 | 80.3% | 77.4% |
| OPM | 5.95% | 3.30pp | 6.82pp |
| NPM | -1.00% | 4.70pp | 3.85pp |
| EPS | -0.04 | 80.0% | 77.8% |
Bausch + Lomb Reports Q2 2026 Results, Raises Full-Year Guidance
29 Jul 2026 · 29 Jul, 4:36 pm
Summary
Bausch + Lomb announced strong second-quarter 2026 financial results, with total revenue reaching $1.394 billion, marking a 9% increase year-over-year. This growth was broad-based across all segments, with notable double-digit increases in the Surgical and Pharmaceuticals divisions. The company reported an improved GAAP Net Loss of $14 million, a significant reduction from the $62 million loss in the same period last year, and saw Adjusted EBITDA rise to $241 million. Based on this performance, Bausch + Lomb is raising its full-year 2026 guidance for both revenue and Adjusted EBITDA.
Key Highlights
- 1
Bausch + Lomb reported second-quarter revenue of $1.394 billion, an increase of 9% as reported and 8% on a constant currency basis compared to the second quarter of 2025.
- 2
The company experienced broad-based growth across all segments, with double-digit revenue growth in Surgical and Pharmaceuticals.
- 3
Surgical segment revenue increased by 19% to $256 million, driven by growth in the premium IOL portfolio.
- 4
Pharmaceuticals segment revenue grew 15% to $354 million, led by MIEBO and XIIDRA.
- 5
GAAP Net Loss attributable to Bausch + Lomb Corporation improved to $14 million for the second quarter of 2026, compared to a net loss of $62 million in the prior year.
- 6
Adjusted EBITDA increased by $50 million to $241 million for the second quarter of 2026.
- 7
The company is raising its full-year 2026 guidance for both revenue and Adjusted EBITDA Excluding Acquired IPR&D.
Management Comments
Brent Saunders
Broad-based revenue growth, leverage in the P&L, margin expansion and conversion to cash flow. These have been themes since we unveiled our three-year plan for growth at Investor Day last November, and in the second quarter progress continued at an accelerated pace.
Informational and educational content only. Not investment advice.